Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

Stopped early · Phase 3

Conditions studied: Breast Cancer

In brief

CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with HER2 negative, HR positive LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting. The primary objective of the study is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone based on progression-free survival (PFS) as assessed by the Independent Radiologic Review Committee (IRC). 685 patients were enrolled.

Key facts

Study ID

NCT03326674

Run by

Odonate Therapeutics, Inc.

People needed

685

Starts

2017-12-21

Expected to finish

2021-06-28

Last updated by the study team

2021-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Female or male patients at least 18 years of age
• Histologically or cytologically confirmed breast cancer
• HER2 negative disease based on local testing: American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines should be utilized for assessing HER2 status
• HR (estrogen receptor [ER] and/or progesterone receptor [PgR]) positive disease based on local testing: ASCO/CAP guidelines should be utilized for assessing HR status
• Measurable disease per RECIST 1.1 or bone-only disease with lytic component
• Patients with bone-only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by computerized tomography (CT) or magnetic resonance imaging (MRI). Patients with bone-only disease without a lytic component (ie, blastic-only metastasis) are not eligible.
• Known metastases to the CNS are permitted but not required. The following criteria apply:
• Patients must be neurologically stable and either off corticosteroids or currently treated with a maximum daily dose of 4 mg of dexamethasone (or equivalent), with no increase in corticosteroid dose within 7 days prior to randomization
• Patients with a history of CNS metastases but with no current evidence of CNS lesions following local therapy are eligible
• Patients may have CNS metastases that are stable or progressing radiologically
• Patients with current evidence of leptomeningeal disease are not eligible
• Patients may have untreated brain metastases or previously treated brain metastases, as long as no immediate local CNS-directed therapy is indicated
• Any prior whole brain radiation therapy must have been completed > 14 days prior to the date of randomization
• Prior stereotactic brain radiosurgery is permitted
• CNS surgical resection must have been completed > 28 days prior to the date of randomization; patient must have complete recovery from surgery
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
• Prior therapy (at least one completed dose) with a taxane-containing regimen in the neoadjuvant or adjuvant setting
• Prior therapy with an anthracycline-containing regimen in the neoadjuvant, adjuvant, or metastatic setting, where indicated by local regulation or Investigator judgment.
• Prior endocrine therapy with or without a CDK 4/6 inhibitor unless endocrine therapy is not indicated (ie, short relapse-free interval while on adjuvant endocrine therapy [endocrine resistance]; rapidly progressing disease/visceral crisis; or endocrine intolerance). Any targeted therapies approved for HER2 negative, HR positive LA/MBC, including everolimus, are permitted as prior therapy. There is no limit to the number of prior endocrine therapies.
• Documented disease recurrence or disease progression of: (a) locally advanced disease that is not considered curable by surgery and/or radiation; or (b) metastatic disease.
• Adequate hematologic, hepatic and renal function, as evidenced by:
• Absolute neutrophil count (ANC) ≥ 1,500/μL without colony-stimulating factor support
• Platelet count ≥ 100,000/μL
• Hemoglobin ≥ 10 g/dL without need for hematopoietic growth factor or transfusion support
• Total bilirubin < 1.5 × upper limit of normal (ULN); does not apply to patients with Gilbert's syndrome

You may not qualify if…

• Two or more prior chemotherapy regimens for advanced disease
• Prior treatment with a taxane in the metastatic setting
• Prior treatment with capecitabine at any dose
• Current evidence of leptomeningeal disease
• Other cancer that required therapy within the preceding 5 years other than adequately treated: (a) non-melanoma skin cancer or in situ cancer; or (b) following approval by the Medical Monitor, other cancer that has a very low risk of interfering with the safety or efficacy endpoints of the study
• Known human immunodeficiency virus infection, unless well controlled. Patients who are on an adequate antiviral regimen with no evidence of active infection are considered well controlled.
• Active hepatitis B or active hepatitis C infection
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study
• Presence of neuropathy > Grade 1 per NCI CTCAE version 5.0
• History of hypersensitivity to taxanes; hypersensitivity to the solvent does not preclude patient participation in this study
• Anticancer treatment, including endocrine therapy, radiotherapy (except stereotactic brain radiosurgery), chemotherapy, biologic therapy, or therapy in an investigational clinical study, ≤ 14 days prior to the date of randomization
• Major surgery ≤ 28 days prior to the date of randomization; patient must have complete recovery from surgery
• Less than 2 weeks or 5 plasma half-lives (whichever is greater) since last use of a medication or ingestion of an agent, beverage or food that is a known clinically relevant strong inhibitor or known clinically relevant inducer of the cytochrome P450 (CYP) 3A pathway (patients should discontinue taking any regularly taken medication that is a strong inhibitor or inducer of the CYP3A pathway)
• History of hypersensitivity or unexpected reactions to capecitabine, other fluoropyrimidine agents or any of their ingredients
• Known dihydropyrimidine dehydrogenase (DPD) deficiency. Testing for DPD deficiency must be performed where required by local regulations, using a validated method that is approved by local health authorities.
• Pregnant or breastfeeding
• If, in the opinion of the Investigator, the patient is deemed unwilling or unable to comply with the requirements of the study
• Treatment with brivudine, sorivudine or its chemically-related analogs ≤ 28 days prior to the date of randomization

Where it is running

• Cancer Treatment Centers of America - Western Regional Medical Center — Goodyear, Arizona, United States
• Arizona Oncology Associates, P.C. - HOPE — Tucson, Arizona, United States
• Genesis Cancer Center — Hot Springs, Arkansas, United States
• Carti Cancer Center — Little Rock, Arkansas, United States
• Pacific Cancer Medical Center — Anaheim, California, United States
• CBCC Global Research, Inc. — Bakersfield, California, United States
• Compassionate Care Research Group — Fountain Valley, California, United States
• California Cancer Associates for Research and Excellence — Fresno, California, United States
• St. Joseph Heritage Healthcare — Fullerton, California, United States
• UCLA Medical Center — Los Angeles, California, United States
• Cancer Care - Torrance Memorial Physician Network — Redondo Beach, California, United States
• Sharp Memorial Hospital — San Diego, California, United States
• University of California San Francisco - Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
• San Luis Obispo Oncology & Hematology Health Center — San Luis Obispo, California, United States
• California Cancer Associates for Research and Excellence — San Marcos, California, United States
• Cancer Research Collaboration and Breast Link — Santa Ana, California, United States
• Stanford Cancer Center / Cancer Clinical Trials — Stanford, California, United States
• Innovative Clinical Research Institute — Whittier, California, United States
• Rocky Mountain Cancer Center — Lakewood, Colorado, United States
• Western Connecticut Health Network — Danbury, Connecticut, United States
• Hartford Healthcare — Hartford, Connecticut, United States
• Sarah Cannon Research Institute - Florida Cancer Specialists — Fort Myers, Florida, United States
• Memorial Healthcare System — Hollywood, Florida, United States
• Cancer Specialists of North Florida — Jacksonville, Florida, United States
• Ironwood Cancer and Research Centers — Chandler, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.